349 related articles for article (PubMed ID: 29708513)
1. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.
Yu J; Qin B; Moyer AM; Nowsheen S; Liu T; Qin S; Zhuang Y; Liu D; Lu SW; Kalari KR; Visscher DW; Copland JA; McLaughlin SA; Moreno-Aspitia A; Northfelt DW; Gray RJ; Lou Z; Suman VJ; Weinshilboum R; Boughey JC; Goetz MP; Wang L
J Clin Invest; 2018 Jun; 128(6):2376-2388. PubMed ID: 29708513
[TBL] [Abstract][Full Text] [Related]
2. Targeting DNA methylation for treating triple-negative breast cancer.
Yu J; Zayas J; Qin B; Wang L
Pharmacogenomics; 2019 Nov; 20(16):1151-1157. PubMed ID: 31755366
[TBL] [Abstract][Full Text] [Related]
3. Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Int J Oncol; 2010 May; 36(5):1235-41. PubMed ID: 20372798
[TBL] [Abstract][Full Text] [Related]
4. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.
Billam M; Sobolewski MD; Davidson NE
Breast Cancer Res Treat; 2010 Apr; 120(3):581-92. PubMed ID: 19459041
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer.
Kala R; Shah HN; Martin SL; Tollefsbol TO
BMC Cancer; 2015 Oct; 15():672. PubMed ID: 26459286
[TBL] [Abstract][Full Text] [Related]
6. Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance.
Dahn ML; Cruickshank BM; Jackson AJ; Dean C; Holloway RW; Hall SR; Coyle KM; Maillet H; Waisman DM; Goralski KB; Giacomantonio CA; Weaver ICG; Marcato P
Mol Cancer Ther; 2020 May; 19(5):1110-1122. PubMed ID: 32156786
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of DNMT1 and ERRα crosstalk suppresses breast cancer via derepression of IRF4.
Vernier M; McGuirk S; Dufour CR; Wan L; Audet-Walsh E; St-Pierre J; Giguère V
Oncogene; 2020 Oct; 39(41):6406-6420. PubMed ID: 32855526
[TBL] [Abstract][Full Text] [Related]
8. The frequency of CpG and non-CpG methylation of Notch3 gene promoter determines its expression levels in breast cancer cells.
Xiao W; Liu X; Niu X; Li C; Guo Y; Tan J; Xiong W; Fan L; Li Y
Exp Cell Res; 2020 Jan; 386(2):111743. PubMed ID: 31770532
[TBL] [Abstract][Full Text] [Related]
9. Aberrant methylation accounts for cell adhesion-related gene silencing during 3-methylcholanthrene and diethylnitrosamine induced multistep rat lung carcinogenesis associated with overexpression of DNA methyltransferases 1 and 3a.
Liu WB; Cui ZH; Ao L; Zhou ZY; Zhou YH; Yuan XY; Xiang YL; Liu JY; Cao J
Toxicol Appl Pharmacol; 2011 Feb; 251(1):70-8. PubMed ID: 21163286
[TBL] [Abstract][Full Text] [Related]
10. Eugenol modulates genomic methylation and inactivates breast cancer-associated fibroblasts through E2F1-dependent downregulation of DNMT1/DNMT3A.
Al-Kharashi LA; Bakheet T; AlHarbi WA; Al-Moghrabi N; Aboussekhra A
Mol Carcinog; 2021 Nov; 60(11):784-795. PubMed ID: 34473867
[TBL] [Abstract][Full Text] [Related]
11. The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells.
Yan F; Shen N; Pang J; Molina JR; Yang P; Liu S
J Biol Chem; 2015 Jul; 290(30):18480-94. PubMed ID: 26085088
[TBL] [Abstract][Full Text] [Related]
12. Kaempferol Modulates DNA Methylation and Downregulates DNMT3B in Bladder Cancer.
Qiu W; Lin J; Zhu Y; Zhang J; Zeng L; Su M; Tian Y
Cell Physiol Biochem; 2017; 41(4):1325-1335. PubMed ID: 28278502
[TBL] [Abstract][Full Text] [Related]
13. miR-155 increases stemness and decitabine resistance in triple-negative breast cancer cells by inhibiting TSPAN5.
Yang LW; Wu XJ; Liang Y; Ye GQ; Che YC; Wu XZ; Zhu XJ; Fan HL; Fan XP; Xu JF
Mol Carcinog; 2020 Apr; 59(4):447-461. PubMed ID: 32096299
[TBL] [Abstract][Full Text] [Related]
14. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Buocikova V; Longhin EM; Pilalis E; Mastrokalou C; Miklikova S; Cihova M; Poturnayova A; Mackova K; Babelova A; Trnkova L; El Yamani N; Zheng C; Rios-Mondragon I; Labudova M; Csaderova L; Kuracinova KM; Makovicky P; Kucerova L; Matuskova M; Cimpan MR; Dusinska M; Babal P; Chatziioannou A; Gabelova A; Rundén-Pran E; Smolkova B
Biomed Pharmacother; 2022 Mar; 147():112662. PubMed ID: 35091237
[TBL] [Abstract][Full Text] [Related]
15. DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity.
Kim HJ; Kim JH; Chie EK; Young PD; Kim IA; Kim IH
Radiat Oncol; 2012 Mar; 7():39. PubMed ID: 22429326
[TBL] [Abstract][Full Text] [Related]
16. 5-aza-2'-Deoxycytidine, a DNA methyltransferase inhibitor, facilitates the inorganic phosphorus-induced mineralization of vascular smooth muscle cells.
Azechi T; Sato F; Sudo R; Wachi H
J Atheroscler Thromb; 2014; 21(5):463-76. PubMed ID: 24441913
[TBL] [Abstract][Full Text] [Related]
17. The cancer-testis gene,
Gu Y; Wang C; Zhu R; Yang J; Yuan W; Zhu Y; Zhou Y; Qin N; Shen H; Ma H; Wang H; Liu X; Hu Z
Cancer Biol Med; 2021 Feb; 18(1):74-87. PubMed ID: 33628586
[TBL] [Abstract][Full Text] [Related]
18. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
19. DNMT1: A key drug target in triple-negative breast cancer.
Wong KK
Semin Cancer Biol; 2021 Jul; 72():198-213. PubMed ID: 32461152
[TBL] [Abstract][Full Text] [Related]
20. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]